clarithromycin has been researched along with montelukast in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 10 (76.92) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Dalvie, D; Loi, CM; Smith, DA | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Demir, K; Duman, N; Kargi, A; Kumral, A; Ozkan, H; Sarioglu, S; Yesilirmak, DC; Yilmaz, O | 1 |
| Elsisi, AE; Hegazy, SK; Mabrouk, MM; Mansour, NO | 1 |
| Phaw, NA; Tsai, HH | 1 |
| Bi, Y; El-Kattan, AF; Eng, H; Kalgutkar, AS; Kimoto, E; Lin, J; Rodrigues, AD; Scialis, R; Tremaine, LM; Varma, MV | 1 |
1 review(s) available for clarithromycin and montelukast
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for clarithromycin and montelukast
| Article | Year |
|---|---|
Effect of clarithromycin and fluconazole on the pharmacokinetics of montelukast in human volunteers.
Topics: Acetates; Administration, Oral; Adult; Analysis of Variance; Anti-Asthmatic Agents; Anti-Bacterial Agents; Antifungal Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Biotransformation; Chromatography, High Pressure Liquid; Clarithromycin; Cross-Over Studies; Cyclopropanes; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Administration Schedule; Drug Interactions; Egypt; Enzyme Inhibitors; Fluconazole; Half-Life; Humans; Leukotriene Antagonists; Male; Membrane Transport Modulators; Membrane Transport Proteins; Metabolic Clearance Rate; Models, Biological; Quinolines; Sulfides | 2012 |
11 other study(ies) available for clarithromycin and montelukast
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Which metabolites circulate?
Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations | 2013 |
Clarithromycin, montelukast, and pentoxifylline combination treatment ameliorates experimental neonatal hyperoxic lung injury.
Topics: Acetates; Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-Steroidal; Bronchopulmonary Dysplasia; Clarithromycin; Cyclopropanes; Disease Models, Animal; Drug Therapy, Combination; Humans; Infant, Newborn; Leukotriene Antagonists; Oxygen Inhalation Therapy; Pentoxifylline; Quinolines; Rats; Sulfides | 2008 |
Eosinophilic gastroenteritis: a challenge to diagnose and treat.
Topics: Acetates; Adult; Anti-Bacterial Agents; Azathioprine; Biopsy; Budesonide; Clarithromycin; Cyclopropanes; Endoscopy; Enteritis; Eosinophilia; Eosinophils; Female; Gastritis; Gastroenteritis; Humans; Leukocyte Count; Macrolides; Mucous Membrane; Quinolines; Sulfides | 2016 |
Transporter-Mediated Hepatic Uptake Plays an Important Role in the Pharmacokinetics and Drug-Drug Interactions of Montelukast.
Topics: Acetates; Animals; Clarithromycin; Cyclopropanes; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Gemfibrozil; Haplorhini; Hepatocytes; Liver; Liver-Specific Organic Anion Transporter 1; Models, Biological; Nucleic Acid Synthesis Inhibitors; Organic Anion Transporters; Quinolines; Rats; Rifampin; Sulfides | 2017 |